Atea Pharmaceuticals, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 48.63M351.37M
Gross Profit 48.63M351.37M
Operating items
Research & Development 10.17M38.02M167.21M81.94M114.24M144.10M
Selling, General & Administrative 4.44M21.64M45.78M48.71M49.92M48.85M
Operating Expenses 14.61M59.66M212.99M130.65M164.16M192.95M
Operating Income -14.61M-11.03M138.38M-130.65M-164.16M-192.95M
EBIT -14.61M-11.03M138.38M-130.65M-164.16M-192.95M
Non-operating items
Interest & Investment Income 0.57M0.08M0.21M11.15M29.22M25.49M
Net income details
EBT -14.03M-10.95M138.59M-119.50M-134.94M-167.46M
Tax Provisions 17.40M-3.59M1.02M0.93M
Profit After Tax -14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Income from Continuing Operations -14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Consolidated Net Income -14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Income towards Parent Company -14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Net Income towards Common Stockholders -14.03M-10.95M121.19M-115.91M-135.96M-168.38M
Additional items
EPS (Basic) -0.00M-0.00M0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 79.24M82.62M83.10M83.29M83.44M84.46M
EBITDA -14.61M-10.95M121.19M-116.59M-135.06M-168.36M
Shares Outstanding 82.44M83.10M
Tax Rate 0.00M0.00M